Drug Pipeline

Resmetirom Clinical Trials

Data updated daily from ClinicalTrials.gov — last refresh 2026-06-12
5
Active Studies
2
Recruiting
3
Phase 3
2
Top Sponsors
2
Changes, 30 Days
What Changed in the Last 30 Days
DetectedTrialChange
2026-05-29 NCT07335601
Study to Evaluate Resmetirom in Post-Liver Transplant Patients With MASH
date change Primary completion pushed: 2027-07 -> 2028-08
2026-05-29 NCT07335601
Study to Evaluate Resmetirom in Post-Liver Transplant Patients With MASH
date change Completion pushed: 2027-12 -> 2029-03
Active Studies by Phase
Phase 3
3
Phase 2
2
Active Trials
NCT IDTitleConditionStatus
Phase 3
NCT04951219 A Phase 3 Study to Evaluate Safety and Biomarkers of Resmetirom (MGL-3196) in Patients… Non-Alcoholic Fatty Liver Disease Active, Not Recruiting
NCT03900429 A Phase 3 Study to Evaluate the Efficacy and Safety of MGL-3196 (Resmetirom) in Patients… NASH - Nonalcoholic Steatohepatitis Active, Not Recruiting
NCT05500222 A Phase 3 Study to Evaluate the Effect of Resmetirom on Clinical Outcomes in Patients… NASH Active, Not Recruiting
Phase 2
NCT07143968 A Study to Evaluate the Use of Resmetirom in Participants With MASLD and HIV MASLD - Metabolic Dysfunction-Associated Steatotic Liver Disease Recruiting
NCT07335601 Study to Evaluate Resmetirom in Post-Liver Transplant Patients With MASH MASH - Metabolic Dysfunction-Associated Steatohepatitis Recruiting
Sponsors Running Resmetirom Trials
Disease Areas
Get alerts when Resmetirom trials change
Status changes, date slips, and new filings — detected daily, delivered to your inbox.
Start monitoring free